



Dimerix

(ASX:DXB)

AusBioInvest 2022 Presentation

Perth, October 2022




Forward looking statements

This presentation includes forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Dimerix to be materially different from the statements in this presentation.

Actual results could differ materially depending on factors such as the availability of resources, the results of clinical studies, the timing and effects of regulatory actions, the strength of competition, the outcome of legal proceedings and the effectiveness of patent protection.

About Dimerix

Dimerix is a biopharmaceutical company developing innovative new therapies in areas with unmet medical needs, with a core focus on developing new therapies to treat inflammatory causes of kidney and respiratory disease

 Lead Drug Candidate DMX-200	 Proven efficacy and safety	 Commercial Ready	 Strong Pipeline
FSGS Phase 3 clinical study recruiting across ~70 sites globally¹	Demonstrated clinical efficacy²; drug well understood, with strong safety profile²	Patent protected products with commercial manufacturing established	Strong outlook with potential for significant value³ upside

Corporate overview

 ASX	Ticker Symbol	ASX:DXB
	Cash Balance (Sep22)*	~A\$12.1 million
	Market Capitalisation	~A\$56 million
	Share price	~A\$0.175
	Total ordinary shares on issue	320,873,666

**includes R&D Incentive Refund \$6m received post quarter end*




Shareholders			
Position	Holder Name	Holding	% IC
1	Mr Peter Meurs	44,179,309	13.8%
2	Merchant Group & Nominees	17,925,000	5.6%
3	Mr Andrew Coates & Mrs Melinda Coates	11,039,000	3.4%
4	Bavaria Bay Pty Ltd	7,316,992	2.3%
5	Yodambao Pty Ltd	6,362,603	2.0%
TOTAL (TOP 5)		86,822,904	27.1%

Development pipeline

Program	Indication	Preclinical	Phase 1	Phase 2	Phase 3	Key milestones
	Focal Segmental Glomerulosclerosis (FSGS)					Phase 2a demonstrated encouraging efficacy & safety ¹ ; Phase 3 underway across ~70 sites globally ² , Part 1 completion anticipated mid-23 ³
DMX-200	Diabetic Kidney Disease					Phase 2 demonstrated promising efficacy and safety ¹ , next study planned with support from Australian Centre for Diabetes Innovation; anticipated H123 ⁴
	Late COVID pneumonia – REMAP-CAP					Study recruitment across Europe, recruitment closed pending analysis by REMAP-CAP, will update market upon receipt ⁵
	Early COVID respiratory – CLARITY 2.0					Study recruitment across India, recruitment closed pending analysis by CLARITY, will update market upon receipt ⁶
DMX-700	Chronic Obstructive Pulmonary Disease (COPD)					Pre-clinical studies reported 80% decrease in lung injury; clinical study design underway with study start anticipated H1 23 ⁷
DMX-xxx	Undisclosed (multiple)					Additional target opportunities identified using Receptor-HIT; preliminary exploratory work underway

Increased interest in kidney transactions: licensing



Phase 3 studies investigating FSGS treatments

No therapies yet approved specifically for FSGS

Study	Drug candidate	Mode of action	Comparator	Primary interim (accelerated approval) endpoint
ACTION3 ¹	DMX-200	CCR2 inhibitor	Placebo	Percent change in uPCR and eGFR slope at week 35
DUPLEX ²	Sparsentan	Dual angiotensin/endothelin A receptor antagonist	Irbesartan	Proportion of patients achieving uPCR $\leq 1.5\text{g/g}$ and $>40\%$ reduction from baseline uPCR at week 36

- DMX-200 given to patients already taking an angiotensin receptor blocker, such as irbesartan (current standard of care)
- Data suggests DMX-200 may be complementary to other development compounds, such as sparsentan³

Focal Segmental Glomerulosclerosis

Focal = some


Segmental = sections

Glomerulo = of the kidney filtering units


Sclerosis = are scarred

A healthy kidney has little to no protein in the urine

Inside a *healthy* kidney



Inside a *damaged* kidney




● = Protein
Protein in the urine = proteinuria)

- A rare disease that attacks part of the kidney, causing inflammation and irreversible scarring¹;
- Leads to permanent kidney damage and eventual end-stage kidney failure, requiring dialysis or transplantation
- US orphan indication: ~40,000 with FSGS and >5,400 diagnosed annually²
- Average orphan drug retails for US\$7,000/month in US³

3 key mechanisms that cause sclerotic kidney disease

AT1R – blocked by angiotensin receptor blocker (ARB)



CCR2 – CCR2 is the receptor for MCP-1; DMX-200 inhibits CCR2 to block attraction of inflammatory cells into the kidneys³

Dimerix' proprietary discovery tool determined a functional interaction between AT1R and CCR2²


Certain kidney cells express both receptors, thus using only 1 compound does not completely block activation and results in only a partial response^{2,3}

DMX-200 unique proposition:
total benefit is greater than the sum of the two individual effects^{2,3}

Less filtering cells cause further hyperfiltration and inflammation

DMX-200 – working on inflammatory signalling pathway

A CCR2 inhibitor working synergistically alongside the current standard of care (AT1R blocker): G protein-coupled receptor (GPCR)



- 4 clinical studies completed to date: positive efficacy signals across studies
- Consistently safe and well tolerated in both healthy volunteers and renal patients (total of 95 patients dosed)
- DMX-200 safety profile and efficacy outcomes compares favourably to compounds currently in development

¹ Thompson et al., (2019) CJASN, 14 (3) 469-481; <https://doi.org/10.2215/CJN.08600718>

² FDA pulication, (2021); FDA approves first drug to decrease urine protein in IgA nephropathy, a rare kidney disease <https://www.fda.gov/drugs/fda-approves-first-drug-decrease-urine-protein-iga-nephropathy-rare-kidney-disease>

³ ASX release: 09May2022

⁴ ASX releases: 14Dec15, 21Nov18, 07Jun21

DMX-200: Phase 2 met primary and secondary endpoints

- **86%** of patients demonstrated reduced proteinuria on DMX-200 versus placebo
- **29%** of patients demonstrated >40% reduction in proteinuria

Efficacy




- No safety concerns – reduced development risk
- DMX-200 compares favourably to compounds currently in development^{2,4}

Safety



Average reduction in proteinuria after 16 weeks treatment on DMX-200 versus placebo compared to standard of care alone in FSGS patients¹




ACTION3 - FSGS phase 3 study design

FSGS CLINICAL STUDY

A randomised, double-blind, multi-centre, placebo-controlled study of renal outcomes of DMX-200 in patients with FSGS receiving an ARB


Global study recruiting across ~70 sites:

- Australia/NZ: 9 sites
- Asia: 9 sites
- Europe: 18 sites
- Latin America: 11 sites
- UK: 6 sites
- USA: 20 sites



Study part 1 recruitment status

Patients recruited*:



- On track to complete Part 1 recruitment and dosing Q4 2022
- Part 1 data outcome anticipated mid-2023



Dimerix

A biopharmaceutical company developing innovative new therapies in areas with unmet medical needs, with a core focus on inflammatory disease treatments such as kidney and respiratory diseases.

Advancing three Phase 3 opportunities

Lead program to report mid 2023

Dimerix HQ
425 Smith St, Fitzroy 3065
Victoria, Australia
T. 1300 813 321
E. investor@dimerix.com

ESG Statement

Dimerix is committed to integrating Environmental, Social and Governance (ESG) considerations across the development cycle of its programs, processes and decision making. The Dimerix commitment to improve its ESG performance demonstrate a strong, well-informed management attitude and a values led culture that is both alert and responsive to the challenges and opportunities of doing business responsibly and sustainably.